King Pharms Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?
KING PHARMS has twenty-seven approved drugs.
There are four US patents protecting KING PHARMS drugs.
There are twenty-eight patent family members on KING PHARMS drugs in nine countries and nine supplementary protection certificates in six countries.
Summary for King Pharms
| International Patents: | 28 |
| US Patents: | 4 |
| Tradenames: | 25 |
| Ingredients: | 23 |
| NDAs: | 27 |
Drugs and US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-006 | Dec 18, 2008 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-005 | Dec 18, 2008 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| King Pharms Llc | PENICILLIN G PROCAINE | penicillin g procaine | INJECTABLE;INJECTION | 060101-002 | Approved Prior to Jan 1, 1982 | RX | No | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| King Pharms | KLEBCIL | kanamycin sulfate | INJECTABLE;INJECTION | 062170-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-004 | May 25, 2001 | 6,555,581 | See Plans and Pricing |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-009 | May 25, 2001 | 6,555,581 | See Plans and Pricing |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-004 | Jan 28, 1991 | 5,061,722 | See Plans and Pricing |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | 7,368,469 | See Plans and Pricing |
| King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-002 | Jan 31, 1996 | 5,656,296 | See Plans and Pricing |
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-006 | May 25, 2001 | 6,555,581 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
| ➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
International Patents for King Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2438907 | See Plans and Pricing |
| Australia | 2002362468 | See Plans and Pricing |
| Australia | 2002258397 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 03070217 | See Plans and Pricing |
| Canada | 2438641 | See Plans and Pricing |
| Australia | 2002332507 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for King Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 13C0062 | France | See Plans and Pricing | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| 0265685 | SPC/GB98/047 | United Kingdom | See Plans and Pricing | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| 1539166 | SPC/GB13/070 | United Kingdom | See Plans and Pricing | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
| 0265685 | C980030 | Netherlands | See Plans and Pricing | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| 1539166 | 2013C/064 | Belgium | See Plans and Pricing | PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626 |
| 0350733 | SPC/GB03/034 | United Kingdom | See Plans and Pricing | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
